$OCUL
OCULAR THERAPEUTIX, INC

2022 Q4 Form 10-Q Financial Statement

#000155837022016610 Filed on November 07, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3
Revenue $14.08M $11.97M
YoY Change 14.36% -1.55%
Cost Of Revenue $1.012M $1.073M
YoY Change -8.66% -18.09%
Gross Profit $13.06M $10.89M
YoY Change 16.63% 0.45%
Gross Profit Margin 92.81% 91.03%
Selling, General & Admin $18.88M $18.72M
YoY Change 13.26% 6.03%
% of Gross Profit 144.54% 171.84%
Research & Development $13.54M $13.72M
YoY Change 7.67% 7.86%
% of Gross Profit 103.67% 125.95%
Depreciation & Amortization $491.0K $509.0K
YoY Change -13.86% -14.31%
% of Gross Profit 3.76% 4.67%
Operating Expenses $32.42M $32.44M
YoY Change 10.86% 6.8%
Operating Profit -$19.36M -$21.54M
YoY Change 7.27% 10.32%
Interest Expense $3.819M $1.797M
YoY Change -73.1% 8.38%
% of Operating Profit
Other Income/Expense, Net $0.00 -$2.644M
YoY Change -100.0% -111.92%
Pretax Income -$15.54M -$24.19M
YoY Change 303.69% -1010.35%
Income Tax
% Of Pretax Income
Net Earnings -$15.54M -$24.19M
YoY Change 303.69% -1010.35%
Net Earnings / Revenue -110.42% -202.16%
Basic Earnings Per Share -$0.31
Diluted Earnings Per Share -$0.20 -$0.31
COMMON SHARES
Basic Shares Outstanding 77.01M 76.97M
Diluted Shares Outstanding 76.98M

Balance Sheet

Concept 2022 Q4 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $102.3M $121.0M
YoY Change -37.68% -32.54%
Cash & Equivalents $102.3M $121.0M
Short-Term Investments
Other Short-Term Assets $4.028M $3.318M
YoY Change -15.22% -14.42%
Inventory $1.974M $1.545M
Prepaid Expenses
Receivables $21.33M $19.80M
Other Receivables $0.00 $0.00
Total Short-Term Assets $129.6M $145.6M
YoY Change -32.24% -28.6%
LONG-TERM ASSETS
Property, Plant & Equipment $9.856M $7.196M
YoY Change 41.69% 4.08%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.764M $1.764M
YoY Change 0.0% 0.0%
Total Long-Term Assets $19.66M $12.96M
YoY Change 44.71% -6.11%
TOTAL ASSETS
Total Short-Term Assets $129.6M $145.6M
Total Long-Term Assets $19.66M $12.96M
Total Assets $149.3M $158.6M
YoY Change -27.14% -27.17%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.123M $5.308M
YoY Change 11.56% 25.01%
Accrued Expenses $24.10M $21.61M
YoY Change 19.76% 11.65%
Deferred Revenue $576.0K $603.0K
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $31.40M $29.27M
YoY Change 19.2% 16.34%
LONG-TERM LIABILITIES
Long-Term Debt $54.01M $53.34M
YoY Change 5.0% 4.96%
Other Long-Term Liabilities $93.00K $29.74M
YoY Change -99.76% -45.36%
Total Long-Term Liabilities $93.00K $83.08M
YoY Change -99.9% -21.06%
TOTAL LIABILITIES
Total Short-Term Liabilities $31.40M $29.27M
Total Long-Term Liabilities $93.00K $83.08M
Total Liabilities $113.9M $112.4M
YoY Change -2.55% -13.84%
SHAREHOLDERS EQUITY
Retained Earnings -$616.8M -$601.3M
YoY Change 13.02% 10.95%
Common Stock $652.2M $647.5M
YoY Change 2.91% 2.9%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $35.38M $46.23M
YoY Change
Total Liabilities & Shareholders Equity $149.3M $158.6M
YoY Change -27.14% -27.17%

Cashflow Statement

Concept 2022 Q4 2022 Q3
OPERATING ACTIVITIES
Net Income -$15.54M -$24.19M
YoY Change 303.69% -1010.35%
Depreciation, Depletion And Amortization $491.0K $509.0K
YoY Change -13.86% -14.31%
Cash From Operating Activities -$16.96M -$13.17M
YoY Change 11.91% 1.44%
INVESTING ACTIVITIES
Capital Expenditures $2.150M -$794.0K
YoY Change -440.73% 187.68%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$2.150M -$794.0K
YoY Change 240.73% 187.68%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 458.0K 374.0K
YoY Change -31.33% -44.92%
NET CHANGE
Cash From Operating Activities -16.96M -13.17M
Cash From Investing Activities -2.150M -794.0K
Cash From Financing Activities 458.0K 374.0K
Net Change In Cash -18.65M -13.59M
YoY Change 23.37% 8.03%
FREE CASH FLOW
Cash From Operating Activities -$16.96M -$13.17M
Capital Expenditures $2.150M -$794.0K
Free Cash Flow -$19.11M -$12.38M
YoY Change 31.58% -2.61%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q3 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2021-01-31#ProductMember
CY2021Q3 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2021-01-31#ProductMember
us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2021-01-31#ProductMember
us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2021-01-31#ProductMember
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
76731940
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
77010385
dei Entity Central Index Key
EntityCentralIndexKey
0001393434
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36554
dei Entity Registrant Name
EntityRegistrantName
Ocular Therapeutix, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-5560161
dei Entity Address Address Line1
EntityAddressAddressLine1
24 Crosby Drive
dei Entity Address City Or Town
EntityAddressCityOrTown
Bedford
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
01730
dei City Area Code
CityAreaCode
781
dei Local Phone Number
LocalPhoneNumber
357-4000
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
OCUL
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
77010385
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
120950000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
164164000
CY2022Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
19802000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
21135000
CY2022Q3 us-gaap Inventory Net
InventoryNet
1545000
CY2021Q4 us-gaap Inventory Net
InventoryNet
1250000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3318000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4751000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
145615000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
191300000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7196000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6956000
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1764000
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1764000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4004000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4867000
CY2022Q3 us-gaap Assets
Assets
158579000
CY2021Q4 us-gaap Assets
Assets
204887000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
5308000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4592000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
21614000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
20121000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
633795000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-601300000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
8000
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
647521000
CY2022Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
603000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1744000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1624000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
29269000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
26337000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
2657000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4610000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5924000
CY2022Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
11594000
CY2021Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
20192000
CY2022Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
13533000
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
13000000
CY2022Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
25192000
CY2021Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
25000000
CY2022Q3 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
28152000
CY2021Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
26435000
CY2022Q3 us-gaap Liabilities
Liabilities
112350000
CY2021Q4 us-gaap Liabilities
Liabilities
116888000
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
77010385
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
76731940
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
8000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-545804000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
46229000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
87999000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
158579000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
204887000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11965000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
12153000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
37419000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
31214000
CY2022Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1073000
CY2021Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1310000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
3528000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
3298000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13719000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12719000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
39919000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
37505000
CY2022Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
10186000
CY2021Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
9576000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
29390000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
26054000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8531000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8077000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
23875000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
24345000
CY2022Q3 us-gaap Costs And Expenses
CostsAndExpenses
33509000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
62249000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-24188000
CY2021Q3 us-gaap Costs And Expenses
CostsAndExpenses
31682000
us-gaap Costs And Expenses
CostsAndExpenses
96712000
us-gaap Costs And Expenses
CostsAndExpenses
91202000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-21544000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-19529000
us-gaap Operating Income Loss
OperatingIncomeLoss
-59293000
us-gaap Operating Income Loss
OperatingIncomeLoss
-59988000
CY2022Q3 us-gaap Investment Income Net
InvestmentIncomeNet
285000
CY2021Q3 us-gaap Investment Income Net
InvestmentIncomeNet
7000
us-gaap Investment Income Net
InvestmentIncomeNet
375000
us-gaap Investment Income Net
InvestmentIncomeNet
27000
CY2022Q3 us-gaap Interest Expense
InterestExpense
1797000
CY2021Q3 us-gaap Interest Expense
InterestExpense
1658000
us-gaap Interest Expense
InterestExpense
5175000
us-gaap Interest Expense
InterestExpense
4991000
CY2022Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-1133000
CY2021Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
23837000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
8598000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
62249000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2644000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
22186000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3797000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
57285000
us-gaap Net Income Loss
NetIncomeLoss
-55496000
us-gaap Net Income Loss
NetIncomeLoss
-2703000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.31
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.03
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.72
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.04
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
76975839
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
76552060
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
76829434
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
76317563
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.31
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.23
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.73
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.75
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
76975839
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
85446886
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
82598666
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
82086795
us-gaap Profit Loss
ProfitLoss
-55496000
us-gaap Profit Loss
ProfitLoss
-2703000
us-gaap Share Based Compensation
ShareBasedCompensation
12730000
us-gaap Share Based Compensation
ShareBasedCompensation
11136000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
3616000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
3440000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
8598000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
514000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2414000
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
482000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4281000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1618000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1851000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-1000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
1000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1333000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
7300000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1433000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-773000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
295000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
21000
ocul Increase Decrease In Operating Lease Assets
IncreaseDecreaseInOperatingLeaseAssets
-863000
ocul Increase Decrease In Operating Lease Assets
IncreaseDecreaseInOperatingLeaseAssets
-715000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
501000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1430000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-293000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
3529000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
1136000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1194000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-997000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-42645000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-50397000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1565000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
563000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1565000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-563000
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
3722000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
482000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
490000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
275000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
4167000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
996000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2184000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-43214000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-48776000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
165928000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
229821000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
122714000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
181045000
us-gaap Interest Paid Net
InterestPaidNet
1521000
us-gaap Interest Paid Net
InterestPaidNet
1443000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
477000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
199000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
87999000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
129000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4209000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-12542000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
79795000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
11000
us-gaap Net Income Loss
NetIncomeLoss
-55496000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
2657000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
87340000
us-gaap Net Income Loss
NetIncomeLoss
-2703000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-601300000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
120950000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-18766000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
65803000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
374000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4240000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-24188000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
46229000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
76095000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1197000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
91000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3086000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
3121000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
83408000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
538000
CY2021Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
490000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4292000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-8481000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
80247000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
678000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3758000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.45pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.45pt;"><span style="margin-bottom:5pt;margin-left:0pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.13;text-align:justify;text-indent:18pt;margin:6pt 0pt 0pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates and assumptions reflected in these financial statements include, but are not </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.13;text-align:justify;margin:0pt;">limited to, revenue recognition, clinical trial accruals and the fair value of derivatives.  Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results may differ from these estimates.  </p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.45pt;"><span style="font-style:italic;font-weight:bold;">Concentration of Credit Risk and of Significant Suppliers and Customers</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.45pt;"><span style="font-style:italic;font-weight:bold;margin-bottom:5pt;margin-left:0pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">The Company is dependent on a small number of third-party manufacturers to supply products for research and development activities in its preclinical and clinical programs and for sales of its products. The Company’s development programs as well as revenue from future product sales could be adversely affected by a significant interruption in the supply of any of the components of these products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">For the three and nine months ended September 30, 2022, three specialty distributor customers accounted for 42%, 30%, and 14%, and 41%, 27% and 18%<span style="white-space:pre-wrap;">, respectively, of the Company’s total gross product revenue, and no other customer accounted for more than 10% of the Company’s total gross product revenue. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">At September 30, 2022, three specialty distributor customers accounted for 44%, 30% and 15% of the Company’s total accounts receivable, and no other customer accounted for more than 10% of the Company’s total accounts receivable at September 30, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">For the three and nine months ended September 30, 2021, three specialty distributor customers accounted for 44%, 28%, and 16%, and 44%, 26% and 15%<span style="white-space:pre-wrap;">, respectively, of the Company’s total gross product revenue, and no other customer accounted for more than 10% of the Company’s total gross product revenue. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">At December 31, 2021, three specialty distributor customers accounted for 42%, 26% and 21% of the Company’s total accounts receivable. No other customer accounted for more than 10% of total accounts receivable at December 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p>
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1764000
CY2021Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1764000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
122714000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
181045000
CY2022Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1306000
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1764000
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1764000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
120950000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
179281000
CY2022Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
317000
CY2021Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
388000
CY2022Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
885000
CY2021Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
605000
CY2022Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
343000
CY2021Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
257000
CY2022Q3 us-gaap Inventory Net
InventoryNet
1545000
CY2021Q4 us-gaap Inventory Net
InventoryNet
1250000
CY2022Q3 ocul Accrued Rebates And Programs Current
AccruedRebatesAndProgramsCurrent
2666000
CY2021Q4 ocul Accrued Rebates And Programs Current
AccruedRebatesAndProgramsCurrent
3615000
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
76975839
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6700000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6597000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1227000
CY2022Q3 ocul Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
1565000
CY2021Q4 ocul Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
1102000
CY2022Q3 ocul Debt Instrument Accrued Interest
DebtInstrumentAccruedInterest
8181000
CY2021Q4 ocul Debt Instrument Accrued Interest
DebtInstrumentAccruedInterest
6475000
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1196000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1105000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
21614000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
20121000
CY2021Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
20192000
us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
8598000
CY2022Q3 us-gaap Derivative Liabilities
DerivativeLiabilities
11594000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
2657000
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
13000000
ocul Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
2000000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
864000
CY2022Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
14136000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-24188000
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
76552060
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
76829434
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
76317563
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.31
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.03
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.72
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.04
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
2657000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-55496000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2703000
CY2021Q3 us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
1113000
us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
3425000
us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
3286000
CY2021Q3 us-gaap Dilutive Securities
DilutiveSecurities
-23837000
us-gaap Dilutive Securities
DilutiveSecurities
-8598000
us-gaap Dilutive Securities
DilutiveSecurities
-62249000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-20067000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-60669000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-61666000
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
76552060
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
76829434
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
76317563
CY2021Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
3125594
CY2021Q3 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
5769232
us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
5769232
us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
5769232
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
85446886
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
82598666
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
82086795
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.23
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.73
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.75
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14846276
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3226777
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14846276
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10948312
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4240000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3758000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12730000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11136000
CY2022Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
22546000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y7M6D

Files In Submission

Name View Source Status
0001558370-22-016610-index-headers.html Edgar Link pending
0001558370-22-016610-index.html Edgar Link pending
0001558370-22-016610.txt Edgar Link pending
0001558370-22-016610-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
ocul-20220930.xsd Edgar Link pending
ocul-20220930x10q.htm Edgar Link pending
ocul-20220930xex31d1.htm Edgar Link pending
ocul-20220930xex31d2.htm Edgar Link pending
ocul-20220930xex32d1.htm Edgar Link pending
ocul-20220930xex32d2.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
ocul-20220930_def.xml Edgar Link unprocessable
ocul-20220930_pre.xml Edgar Link unprocessable
ocul-20220930_lab.xml Edgar Link unprocessable
ocul-20220930x10q_htm.xml Edgar Link completed
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ocul-20220930_cal.xml Edgar Link unprocessable